US Pharma MarketingThe post NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial appeared first on Clinical Trials Arena.
NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial
NeuroSense now has FDA clearance to take PrimeC to Phase III in ALS, as competition in the indication intensifies. PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several drugs in late-stage trials. NeuroSense is progressing PrimeC to a pivotal trial in ALS following FDA clearance. Credit: Sheeyla / Shutterstock.com. Massachusetts-based biotech NeuroSense Therapeutics’ combination amyotrophic lateral sclerosis (ALS) therapy, PrimeC, has been shown to reduce a key biomarker of progression in the neurodegenerative disease – a development that an ALS specialist calls “compelling”. During the Phase IIb PARADIGM study (NCT05357950),…
NeuroSense now has FDA clearance to take PrimeC to Phase III in ALS, as competition in the indication intensifies.
Source: Clinical Trials Arena